Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

Discovery, total chemical synthesis, and validation of “mirror-image” D-Nanobodies

Project description

Tiny synthetic antibody fragments as an alternative to monoclonal antibodies

Antibodies are proteins produced by the immune system that circulate in the bloodstream to fight infection by foreign ‘invaders.’ Monoclonal antibodies are synthetic antibodies that mimic the body’s natural ones. They hold great promise for the treatment of a plethora of diseases. However, they continue to face many challenges including long half-lives causing unwanted immune system activation and large size hindering their ability to leave the blood and enter tumours. With the support of the Marie Skłodowska-Curie Actions programme, the MirrorBody project will develop synthetic nanobodies, mimicking the smallest naturally derived antibody fragments with antigen-binding activity and shorter half-lives, to overcome these challenges.

Objective

The central role of molecularly-targeted therapeutics and imaging probes in translational research entails the development of an ever-growing arsenal of “chemical biologics” endowed with optimal in vivo properties. In this regard, mAbs and their derivatives (e.g. ADCs) still suffer from unsettled drawbacks involving difficulties in production and characterization, leading to heterogeneous conjugates in terms of size, potency and toxicity. Chemical modifications on mAbs are highly unreliable due to their complex structure: a central problem in this discipline, where heterogeneous drug-to-antibody ratio (DAR) and conjugation site represent significative limitations. Immunogenicity is a major drawback which affects humanized, as well as fully-human mAbs, and is exacerbated by long half-lives. Cases of unwanted activation of the immune system reportedly degenerated to life-threatening conditions such as acute anaphylaxis, serum sickness and cytokine release syndrome. Their bulky size (≈150 kDa) hinders their extravasation, impairing their efficiency to enter tumors.
Nanobodies (Nbs) are the smallest naturally-derived antibody fragments (≈13-14 kDa) that retain antigen-binding affinities in the same range of mAbs (nM to pM affinity range) while having extremely reduced half-lives ( ≈ 15 min.) when not bound to their target, thanks to a fast renal excretion.
MirrorBody intends to push the boundaries of targeted “chemical biologics” via an interdisciplinary approach that exploits both immunology and synthetic chemistry techniques for the generation of synthetic D-nanobodies that bind natural L-targets with high affinity. Such unprecedented synthetic D-Nbs will be endowed with improved biocompatibility, and will enable “plug-and-play” approaches for the controlled conjugation of diverse moieties.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) HORIZON-MSCA-2021-PF-01

See all projects funded under this call

Coordinator

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 195 914,88
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data
My booklet 0 0